Verastem Joins The Public Markets With A Strong IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.